Lori Solomon

1 week ago | medicalxpress.com | Lori Solomon |Andrew Zinin

Male athletes with high-volume exercise training have a higher burden of calcified plaque than male nonathletes, according to a review published in the June issue of JACC: Advances. Ahmed Abdelaziz, M.D., from the Medical Research Group of Egypt at the Negida Academy in Arlington, Massachusetts, and colleagues evaluated the impact of endurance exercise on coronary atherosclerosis assessed by cardiac computed tomography in athletes and nonathletes.

1 week ago | medicalxpress.com | Lori Solomon |Andrew Zinin

Sedentary behavior among U.S. adults fell between 2013 and 2020 but plateaued after that, according to a research letter published online May 21 in the Journal of the American Medical Association. Sidong Li, Ph.D., from the University of Science and Technology of China in Hefei, and colleagues analyzed data from participants in the National Health and Nutrition Examination Survey to estimate changes in sedentary time among U.S. adults from 2013 to 2023.

1 week ago | medicalxpress.com | Lori Solomon |Andrew Zinin

Physically active adults have a lower risk for overactive bladder compared with inactive adults, according to a study published online May 10 in Scientific Reports. Tianen Wu and Binbin Xu, both from Jinjiang Municipal Hospital in Quanzhou, China, explored the association between physical activity and the risk for overactive bladder. The analysis included data collected from 17,050 participants in the National Health and Nutrition Examination Surveys (2007 to 2018).

1 week ago | medicalxpress.com | Lori Solomon |Sadie Harley |Andrew Zinin

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. Through a supplemental new drug application, Zoryve foam was approved as a once-daily, steroid-free topical treatment.

1 week ago | medicalxpress.com | Lori Solomon |Stephanie Baum |Andrew Zinin

Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell lung cancer (ES-SCLC) live longer versus maintenance therapy with atezolizumab alone, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Luis G.